#1 Clinical Trials Search in Europe

[18F]Fapi-74

[18F]Fapi-74 is an innovative radioactive tracer being studied in clinical trials for its potential to improve cancer detection and diagnosis. This article explores how [18F]Fapi-74 is being used in PET/CT imaging to detect cancer spread and evaluate treatment effectiveness in patients with pancreatic, colon, prostate, and other cancers. We’ll discuss the ongoing research, potential benefits, and what patients can expect from these trials.

Table of Contents

What is [18F]FAPI-74?

[18F]FAPI-74 is an innovative diagnostic tool currently being studied for its potential in detecting various types of cancer and lung fibrosis[1][2][3][4]. It is a type of radioactive tracer used in a special imaging technique called PET/CT (Positron Emission Tomography/Computed Tomography). This substance is not yet approved for widespread clinical use and is being evaluated in research studies to determine its effectiveness.

How it Works

[18F]FAPI-74 works by targeting a specific protein called Fibroblast Activation Protein (FAP). This protein is often found in higher amounts in cancerous tissues and areas of inflammation or fibrosis (scarring). When injected into the body, [18F]FAPI-74 attaches to these FAP proteins, allowing doctors to see potential problem areas more clearly on PET/CT scans[3].

Conditions Being Studied

Research is currently focusing on the use of [18F]FAPI-74 PET/CT for several conditions:

  • Pancreatic cancer: To detect the spread of cancer to nearby lymph nodes and distant parts of the body[1].
  • Colon cancer: To identify cancer that has spread to lymph nodes or other areas[2].
  • Prostate cancer: To evaluate how the cancer has spread in patients with advanced disease[3].
  • Lung fibrosis in connective tissue diseases: To detect early signs of lung scarring in patients with certain autoimmune conditions[4].

How [18F]FAPI-74 is Administered

[18F]FAPI-74 is given as a solution for injection, typically through an intravenous (IV) route. This means it’s injected directly into a vein, usually in your arm. The dose can vary depending on the specific study, but ranges from about 250 to 400 MBq (megabecquerels, a unit of radioactivity)[1][2][3][4].

Potential Benefits

The potential benefits of [18F]FAPI-74 PET/CT include:

  • More accurate detection of cancer spread, which could help in planning treatments[1][2].
  • Earlier detection of lung fibrosis in patients with certain autoimmune diseases, potentially allowing for earlier treatment[4].
  • Improved understanding of how different cancers behave and spread in the body[3].

Ongoing Research

Several clinical trials are currently underway to evaluate the effectiveness of [18F]FAPI-74:

  • A study comparing [18F]FAPI-74 to other imaging techniques for detecting prostate cancer spread[3].
  • Research on using [18F]FAPI-74 to predict which patients with connective tissue diseases might develop progressive lung fibrosis[4].
  • Studies assessing how well [18F]FAPI-74 can detect lymph node involvement in pancreatic and colon cancers[1][2].

Who Can Participate in Studies?

Eligibility for [18F]FAPI-74 studies varies depending on the specific research, but generally includes:

  • Adults aged 18-85 years old
  • Patients with confirmed or suspected cancer (depending on the study)
  • Individuals with certain autoimmune diseases (for the lung fibrosis study)
  • Generally good overall health (usually measured by a WHO performance score of 0-2, which indicates the patient’s ability to care for themselves and carry out daily activities)

Patients who are pregnant, breastfeeding, or have certain medical conditions that prevent whole-body PET/CT imaging are typically not eligible for these studies[1][2][3][4].

Conclusion

[18F]FAPI-74 is a promising new tool in the field of medical imaging. While it’s still in the research phase, early studies suggest it could significantly improve our ability to detect and monitor certain cancers and lung conditions. As research continues, we may learn more about its potential uses and benefits for patients.

Aspect Details
Drug Name [18F]Fapi-74
Type Radioactive tracer for PET/CT imaging
Administration Intravenous injection
Cancers Studied Pancreatic, Colon, Prostate, Connective Tissue Disease-related
Primary Objectives Detect lymph node metastasis, evaluate distant metastases, assess cancer spread accuracy
Target Population Adults aged 18-85 with specific cancer diagnoses or high risk of certain cancers
Key Exclusions Pregnancy, breastfeeding, certain medical conditions, allergies to tracer components
Dosage Range 250-400 MBq (megabecquerels)
Trial Phases Primarily diagnostic efficacy studies (equivalent to Phase II)

FAQ

  • What is [18F]Fapi-74 and how is it used in cancer diagnosis? [18F]Fapi-74 is a radioactive tracer used in PET/CT imaging. It's injected into the patient's bloodstream and attaches to specific proteins found in cancer cells, helping doctors see where cancer has spread in the body more clearly than with standard imaging techniques.
  • What types of cancer are being studied with [18F]Fapi-74? Current clinical trials are focusing on pancreatic cancer, colon cancer, prostate cancer, and cancers associated with connective tissue diseases. However, its potential use may extend to other cancer types in future studies.
  • How accurate is [18F]Fapi-74 in detecting cancer spread? While accuracy is still being studied, researchers aim for [18F]Fapi-74 PET/CT to have at least 70% sensitivity in detecting metastatic lymph nodes. This means it should correctly identify cancer spread in at least 7 out of 10 cases where it's present.
  • Are there any risks associated with [18F]Fapi-74 use in clinical trials? As with any medical procedure involving radiation, there are some risks. However, the dose used is carefully controlled. Patients with allergies to the tracer components, those who are pregnant or breastfeeding, and individuals with certain medical conditions may not be eligible for these trials.
  • How does [18F]Fapi-74 compare to other diagnostic methods? One of the goals of these trials is to compare [18F]Fapi-74 PET/CT with other imaging techniques like standard CT, MRI, and bone scans. Researchers are particularly interested in how it compares to other PET tracers, such as those used for prostate cancer detection, in terms of sensitivity and accuracy.

Ongoing Clinical Trials on [18F]Fapi-74

  • Study of [18F]FAPI-74 PET/CT Imaging in Patients with Connective Tissue Disease at Risk of Lung Fibrosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • PET/CT: Positron Emission Tomography/Computed Tomography, a combined imaging technique that provides detailed pictures of both the structure and function of tissues and organs in the body.
  • Metastasis: The spread of cancer cells from the original (primary) tumor to other parts of the body through the blood or lymph system.
  • Lymph node: Small structures that work as filters for harmful substances in the body. They contain immune cells that can trap cancer cells or bacteria that are traveling through the body in lymph fluid.
  • Radioactive tracer: A substance containing a radioactive atom that can be detected by special cameras, allowing doctors to see how it moves through the body and where it collects.
  • Sensitivity: In medical testing, sensitivity refers to the ability of a test to correctly identify those with the disease (true positive rate).
  • Fibroblast activation protein (FAP): A protein found on the surface of certain cells, particularly in cancer-associated fibroblasts, which [18F]Fapi-74 targets to help identify cancerous areas.
  • Connective tissue disease: A group of disorders involving the tissue that supports organs and other parts of the body, often associated with autoimmune conditions.
  • Interstitial lung disease (ILD): A group of disorders that cause scarring of the lungs, making it difficult to breathe and get enough oxygen into the bloodstream.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-18ffapi-74-pet-ct-for-detecting-lymph-node-spread-in-patients-with-pancreatic-cancer/
  2. http://clinicaltrials.eu/trial/study-on-the-accuracy-of-18ffapi-74-pet-ct-for-detecting-lymph-node-spread-in-patients-with-colon-cancer/
  3. http://clinicaltrials.eu/trial/study-on-metastatic-prostate-cancer-evaluating-18ffapi-74-and-piflufolastat-18f-for-patients-with-advanced-disease/
  4. http://clinicaltrials.eu/trial/study-on-early-detection-of-lung-fibrosis-in-connective-tissue-disease-patients-using-18ffapi-74/